<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35057">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789320</url>
  </required_header>
  <id_info>
    <org_study_id>CLS1001-101</org_study_id>
    <nct_id>NCT01789320</nct_id>
  </id_info>
  <brief_title>Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis</brief_title>
  <official_title>Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clearside Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clearside Biomedical, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the safety and tolerability of a single microinjection
      of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who
      have non-infectious uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2, open-label study designed to evaluate the safety and tolerability of a
      microneedle injection of triamcinolone acetonide (TA) into the SCS.  The subjects enrolled
      in this study will be chosen from subjects with non-infectious intermediate, posterior and
      pan-uveitis. The injection will only be administered to a single eye via the Clearside
      Biomedical proprietary microneedle into the SCS.  The dose of TA to be injected is 4 mg of
      currently approved TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL).  The
      study design includes 10 clinic visits over 27 weeks.  Subjects will be followed for 26
      weeks following treatment with TRIESENCE®.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Number of adverse events at 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Number of adverse events at 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central subfield thickness using optical coherence tomography (OCT)</measure>
    <time_frame>Change from baseline at 8 weeks and 26 weeks.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitreous haze grade</measure>
    <time_frame>Change from baseline at 8 weeks and 26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intraocular pressure (IOP)</measure>
    <time_frame>Change from baseline in IOP at 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Uveitis</condition>
  <condition>Intermediate Uveitis</condition>
  <condition>Posterior Uveitis</condition>
  <condition>Panuveitis</condition>
  <condition>Noninfectious Uveitis</condition>
  <arm_group>
    <arm_group_label>triamcinolone acetonide (Triesence®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone acetonide (Triesence®)</intervention_name>
    <description>4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space</description>
    <arm_group_label>triamcinolone acetonide (Triesence®)</arm_group_label>
    <other_name>triamcinolone acetonide</other_name>
    <other_name>TA</other_name>
    <other_name>Triesence</other_name>
    <other_name>corticosteroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of non-infectious intermediate, posterior or pan-uveitis

        Exclusion Criteria:

          -  any ocular trauma within the past 6 months in the study eye

          -  any injection of intraocular corticosteroids or steroid implant or the Ozurdex®
             implant in the 6 months prior to the study treatment, or any prior use of Retisert™
             in the study eye

          -  any uncontrolled systemic disease that would preclude participation in the study or
             put the subject at risk due to study treatment or procedures

          -  have a known HIV infection or other immunodeficiency disease for which corticosteroid
             therapy would be contraindicated

          -  are monocular

          -  have ocular hypertension

          -  history of any intraocular surgery in the study eye

          -  presence of an anterior staphyloma in the study eye
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michelle Widmann</last_name>
    <phone>678-270-3631</phone>
    <email>michelle.widmann@clearsidebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Klotz</last_name>
    <phone>678-270-3631</phone>
    <email>melanie.klotz@clearsidebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Castro-Malek</last_name>
      <phone>312-695-0252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Greer</last_name>
      <phone>402-559-1851</phone>
      <email>lisa.greer@UNMC.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Baynes</last_name>
      <phone>216-444-2566</phone>
      <email>BAYNESK@ccf.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>August 13, 2013</lastchanged_date>
  <firstreceived_date>February 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveitis</keyword>
  <keyword>intermediate uveitis</keyword>
  <keyword>posterior uveitis</keyword>
  <keyword>panuveitis</keyword>
  <keyword>noninfectious uveitis</keyword>
  <keyword>microneedle</keyword>
  <keyword>suprachoroidal space</keyword>
  <keyword>SCS</keyword>
  <keyword>inflammation</keyword>
  <keyword>ocular inflammatory conditions</keyword>
  <keyword>triamcinolone acetonide</keyword>
  <keyword>TA</keyword>
  <keyword>Triesence</keyword>
  <keyword>injection</keyword>
  <keyword>IVT</keyword>
  <keyword>intravitreal</keyword>
  <keyword>corticosteroid</keyword>
  <keyword>sympathetic ophthalmia</keyword>
  <keyword>temporal arteritis</keyword>
  <keyword>vitreous haze</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Panuveitis</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Chorioretinitis</mesh_term>
    <mesh_term>Uveitis, Intermediate</mesh_term>
    <mesh_term>Pars Planitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
